136 related articles for article (PubMed ID: 1870427)
1. Blunted growth hormone (GH) responsiveness to GH-releasing hormone in obese patients: influence of prolonged administration of the serotoninergic drug fenfluramine.
Argenio GF; Bernini GP; Sgró M; Vivaldi MS; Del Corso C; Santoni R; Franchi F
Metabolism; 1991 Jul; 40(7):724-7. PubMed ID: 1870427
[TBL] [Abstract][Full Text] [Related]
2. Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramine does not restore growth hormone responsiveness in obese women.
Kars ME; Pijl H; Cohen AF; Frölich M; Schoemaker HC; Brandenburg HC; Meinders AE
Clin Endocrinol (Oxf); 1996 May; 44(5):541-6. PubMed ID: 8762730
[TBL] [Abstract][Full Text] [Related]
3. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
Cordido F; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
[TBL] [Abstract][Full Text] [Related]
4. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
Procopio M; Maccario M; Grottoli S; Oleandri SE; Boffano GM; Camanni F; Ghigo E
Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
[TBL] [Abstract][Full Text] [Related]
5. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity.
Ghigo E; Procopio M; Boffano GM; Arvat E; Valente F; Maccario M; Mazza E; Camanni F
Metabolism; 1992 May; 41(5):560-3. PubMed ID: 1588839
[TBL] [Abstract][Full Text] [Related]
6. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
[TBL] [Abstract][Full Text] [Related]
7. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
[TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
[TBL] [Abstract][Full Text] [Related]
9. Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II Diabetic patients.
Giustina A; Bresciani E; Tassi C; Girelli A; Valentini U
Metabolism; 1994 Jul; 43(7):893-8. PubMed ID: 8028515
[TBL] [Abstract][Full Text] [Related]
10. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
[TBL] [Abstract][Full Text] [Related]
11. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.
Kelijman M; Frohman LA
J Clin Endocrinol Metab; 1988 Mar; 66(3):489-94. PubMed ID: 3127415
[TBL] [Abstract][Full Text] [Related]
12. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
[TBL] [Abstract][Full Text] [Related]
13. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
[TBL] [Abstract][Full Text] [Related]
14. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
Maccario M; Procopio M; Grottoli S; Oleandri SE; Boffano GM; Taliano M; Camanni F; Ghigo E
Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
[TBL] [Abstract][Full Text] [Related]
16. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children.
Ghigo E; Mazza E; Corrias A; Imperiale E; Goffi S; Arvat E; Bellone J; De Sanctis C; Müller EE; Camanni F
Metabolism; 1989 Jul; 38(7):631-3. PubMed ID: 2500577
[TBL] [Abstract][Full Text] [Related]
17. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
Cordido F; Peñalva A; Peino R; Casanueva FF; Dieguez C
Metabolism; 1995 Jun; 44(6):745-8. PubMed ID: 7783658
[TBL] [Abstract][Full Text] [Related]
18. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
19. Impaired growth hormone response to insulin-induced hypoglycaemia in obese patients: restoration blocked by ritanserin after fenfluramine administration.
Bernini GP; Argenio GF; Vivaldi MS; Del Corso C; Birindelli R; Luisi M; Franchi F
Clin Endocrinol (Oxf); 1990 Apr; 32(4):453-9. PubMed ID: 2112069
[TBL] [Abstract][Full Text] [Related]
20. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
Cordido F; Peñalva A; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
